August #126 : Less Than Zerit - by Tim Murphy

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Archives » POZ Magazine issues




Table of Contents
 

Vital Signs

Martha Living

ONLINE EXCLUSIVE: Ready or Not




Double Positive

Less Than Zerit

Butt Out

Just Dose It

Who’s Your Daddy?

Beauty and the Beach

I Give At The Office

Giving It Up

Dial-up Prevention

The Ryan White Pages

Escape Artist




Badge of Dishonor

The Tribe Has Spoken

Iranian Bombshell

Monkey Business

Bungle in the Jungle

Dancing With the Stars

Better In The Bahamas?

Doggone It

Fear Factor

The Blame Game




Editor's Letter-August 2006

Mailbox-August 2006

POZ.com Personals Catch of the Month-August 2006



 

Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV



email print

August 2006


Less Than Zerit

by Tim Murphy

Cutting a problematic HIV med’s dose may cut side effects here and abroad

To dodge the infamous side effects of the nuke (NRTI) d4T (Zerit), a widely available HIV med, some physicians are recommending that providers worldwide reduce doses of the drug from the standard 40 mg to 30 mg twice daily, or from 30 mg to 20 mg for those weighing 132 pounds or less.

The docs, from New York City’s AIDS-savvy St. Vincent’s Hospital, have issued a paper citing several studies, including their own, showing that the lower dose of Zerit was just as effective and lacked the common side effects of lipoatrophy (facial- and limb-fat loss) and peripheral neuropathy (arm, leg and foot numbness and pain)—all linked to d4T in numerous studies.

For people who are doing OK on d4T, “I’d consider lowering the dose to prevent future side effects,” says Antonio Urbina, MD, of the St. Vincent’s group. Ditto for drug-resistant people for whom d4T is still an option. “Before combo therapy,” Urbina says, “we used to try to find the maximum tolerated dose.” Now that therapy is better at controlling HIV, he says, it’s time to talk about “maximum effective doses.”

In the U.S., HIV med choices are plentiful and people can avoid d4T altogether. But the lower dose may help developing countries, where options are fewer. There, generic d4T is popular as Stavir or in the three-drug combo Triomune. In response to increasing evidence of d4T side effects in southern Africa, says Francois Venter, MD, president of the region’s HIV Clinicians Society, “Many of us favor the lower dose.”

There are versions of Stavir and Triomune with 30 mgs of d4T along with the 40 mg variety, but no 20 mg pill for those with lower body weight. It might be time for manufacturers to drop the dose.                    


[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Poll
Is youth leadership important in the HIV/AIDS fight?
Yes
No

Survey
Smoke Signals

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.